Clinical trials: Brain Stroke
Cerebrovascular Accident
Anti-MAG First Administration to Human
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration.
- Trial name
- NCT00622609
- Testing
- GSK249320A
- Where
- 2 sites in United States, Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cerebrovascular Accident
Headache Study to Compare Aggrenox Full Dose and Reduced Dose
Tolerability of a four weeks treatment with Aggrenox® modified release capsules b.i.d, compared to reduced dose during the first two weeks of treatment in a double-blind, randomized controlled parallel group comparison trial…
- Trial name
- NCT00274586
- Testing
- Aggrenox® modified release capsules
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Stroke, Hypertension
DELPHI in Subjects at Risk for Stroke and Dementia
The DELPhi system is a software device that is used for the noninvasive evaluation of brain plasticity and connectivity. The DELPhi software uses EEG and TMS devices as accessories.
- Conditions
- Stroke, Hypertension, Diabete Mellitus, Dyslipidemias
- Trial name
- NCT03884647
- Testing
- DELPhI system
- Where
- 4 sites in United States, Israel
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Fabry Disease
Replagal Enzyme Replacement Therapy for Children With Fabry Disease
Primary Objective(s): To assess the safety of Replagal at a dose of 0.2 mg/kg administered over 40 (+/-10) minutes in children with Fabry disease To assess the effect of Replagal on heart rate variability in patients 7 to 17…
- Trial name
- NCT00084084
- Testing
- Agalsidase alfa
- Where
- 14 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Shire
Ischemic Stroke
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants
This study is a randomized, double-blind, placebo-controlled clinical trial featuring both single ascending dose (SAD), food effect and multiple ascending dose (MAD) phases intended to evaluate the safety, tolerability, PK, PD…
- Trial name
- NCT07371455
- Testing
- LWP779
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Longwood Pharmaceuticals (Hangzhou) Co., Ltd.
Ischemic Stroke
Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke
That the Jan Medical Nautilus NeuroWaveTM system provides significantly higher sensitivity to hyper acute ischemic stroke than does CT.
- Trial name
- NCT01643525
- Testing
- Nautilus NeuroWaveTM System
- Where
- 3 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Jan Medical, Inc.
Atherosclerosis, Cardiovascular Disease
A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Trial name
- HEART-3 (NCT07839936)
- Testing
- VERVE-102
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Verve Therapeutics, Inc.
Stroke, Acute
Pilot Study of Acute Stroke Using the Brainpulse™
The aim of this pilot study is to collect data on stroke patients and non-stroke patients or healthy volunteers using the BrainPulse Stroke Monitor.
- Trial name
- NCT03235271
- Testing
- BrainPulse Device
- Where
- 3 sites in United States
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Jan Medical, Inc.
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism on anticoagulant therapy who have changed their therapeutic…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- SILVER-AP (NCT02470767)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 792 people
- Sponsor
- Bayer
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Stroke, Acute
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.
- Trial name
- NCT04701684
- Testing
- Direct to Angio Suite (DTAS) Philips' CBCT triage, Conventional CT/MR triage
- Where
- 24 sites in United States, Argentina and 8 more
- Volunteers
- 594 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Venous Thromboses, Ischemic Stroke
OsciPulse D-dimer Efficacy Trial
The purpose of this study is to assess the safety and efficacy of the OsciPulse System in reducing serum d-dimer levels in hospitalized ischemic stroke patients.
- Trial name
- NCT05389488
- Testing
- OsciPulse system, Flowtron ACS900
- Where
- United States
- Sponsor
- OsciFlex LLC
Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical…
- Trial name
- NCT07749170
- Testing
- Endovascular Thrombectomy, Medical Management
- Where
- 7 sites in United States
- Volunteers
- 250 people
- Sponsor
- Penumbra Inc.
Stroke, Brain Injuries, Traumatic
The Effects of Lifebloom One on Physical Activity After Acquired Brain Injury
The goal of this clinical trial is to evaluate the effects of Lifebloom One in people who have suffered a stroke or a traumatic brain injury.
- Trial name
- LBO_LCA (NCT05977270)
- Testing
- Lifebloom One
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Lifebloom
Stroke, Brachial Plexus Injury
Outcome Measures Study on an Adult Myoelectric Elbow-Wrist-Hand Orthosis
The objective of this study is to evaluate the therapeutic and functional gains of a myoelectric elbow-wrist-hand orthosis for adult individuals with upper limb impairments using repeated measures studies that combines both gross…
- Conditions
- Stroke, Brachial Plexus Injury, Spinal Cord Injuries, Neurological Disease
- Trial name
- NCT04900896
- Testing
- Myoelectric Elbow-Wrist-Hand Orthosis
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Myomo
Acute Ischemic Stroke
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy of recombinant human tissue-type plasminogen activator variant (rhTNK-tPA) (0.25 mg/kg, maximum dose…
- Trial name
- TRACE-LATE (NCT07201688)
- Testing
- rhTNK-tPA
- Where
- China
- Volunteers
- 890 people
- Sponsor
- CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.
Endovascular Thrombectomy, Ischemic Cerebrovascular Accident
A Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke
The MaTRISS 2 study is a phase 2 randomized, double-blinded and placebo-controlled trial aimed at recruiting 60 subjects (30 placebo and 30 active) from 15 stroke centers in France.
- Trial name
- MATRISS-II (NCT06700824)
- Testing
- OTR4132
- Where
- 15 sites in France
- Volunteers
- 60 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Stroke, Ischemic, Stroke Hemorrhagic
Evaluation of the Effectiveness and Safety of Keeogo™ Dermoskeleton in Subjects With Mobility Impairments Due to Stroke
A multi-site, interventional, non-comparative, single-arm trial to evaluate the safety of the Keeogo™ Dermoskeleton in subjects with hemiparesis due to ischemic or hemorrhagic stroke.
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Hemiparesis
- Trial name
- NCT03986320
- Testing
- Keeogo™ Dermoskeleton
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- B-Temia, Inc.
Ischemic Stroke
A Study of NCS-01 in Patients With Acute Ischemic Stroke
This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset.
- Trial name
- NCT03915431
- Testing
- NCS-01
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NC Medial Research Inc
Ischaemic Stroke
SITS-IVT in Patients >80 Years Study
A non-interventional post-approval study on Safe Implementation of Treatment in Stroke - International Stroke Thrombolysis Register (SITS-ISTR) existing data of intravenous recombinant tissue plasminogen Activator (rt-PA) (0.9…
- Trial name
- SITS_ELDERLY (NCT04260347)
- Testing
- Alteplase
- Where
- Sweden
- Volunteers
- 1,655 people
- Sponsor
- Boehringer Ingelheim